Incannex Healthcare Inc. (IXHL): R&D Expense

Annual figures by period end, from SEC filings.

$5.21M
Year ended 2026-06-30
$5.21M
Trailing 12 months to 2026-09-30
-6.2%
3-year compound annual growth
$12.88M2023-06-30: $6.31M2024-06-30: $12.88M2025-06-30: $10.75M2026-06-30: $5.21M$5.21M
2023-06-30 R&D Expense (USD) 2026-06-30
Period endedR&D ExpenseChange YoYSource filing
2026-06-30$5.21M-51.5%2026-09-25, From 2025-07-01
2025-06-30$10.75M-16.6%2026-09-25, From 2024-07-01
2024-06-30$12.88M+104.1%2025-09-29, From 2023-07-01
2023-06-30$6.31Mn/a2024-09-30, From 2022-07-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Incannex Healthcare Inc. (IXHL)2026-06-30$5.21M-51.5%
Abbott Laboratories (ABT)2025-12-31$2.94B+3.4%
Bristol Myers Squibb Co (BMY)2025-12-31$9.95B-10.8%
Eli Lilly & Co (LLY)2025-12-31$13.34B+21.3%
Pfizer Inc (PFE)2025-12-31$10.44B-3.6%
Johnson & Johnson (JNJ)2025-12-28$14.66B-14.9%
Nature's Sunshine Products Inc (NATR)2025-12-31$1.90M+11.8%
Merck & Co., Inc. (MRK)2025-12-31$15.79B-12.0%
Provectus Biopharmaceuticals, Inc. (PVCT)2025-12-31$1.90M-7.5%

Compare IXHL, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗